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Abstract In stroke patients higher levels of plasma
fibrinogen are associated with increased risk of unfavour-
able functional outcome and short-term mortality. The aim
of our study was to determine the relationship between
plasma fibrinogen level and long-term risk of death in
ischemic stroke patients. Seven hundred thirty six patients
(median age 71; 47.1 % men) admitted to the stroke unit
within 24 h after stroke were included. Plasma fibrinogen
level was measured on day 1 of hospitalisation. Hyperfi-
brinogenemia was defined as plasma fibrinogen concen-
tration [3.5 g/L. The maximal follow-up period was
84 months. Hyperfibrinogenemia was found in 25.0 % of
patients. On multivariate logistic regression analysis, after
adjustment for age, stroke severity, atrial fibrillation,
smoking, white blood cell count, fever, in-hospital pneu-
monia and hyperglycemia, hyperfibrinogenemia was asso-
ciated with increased case fatality (HR 1.71, 95 % CI
1.29–2.26, P \ 0.01). Hyperfibrinogenemia predicts the
long-term risk of death in ischemic stroke patients.
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Introduction
Fibrinogen is a coagulation factor, a major determinant of
plasma viscosity and key factor for platelet activation. It
belongs also to acute phase proteins. A numerous studies
have demonstrated that plasma fibrinogen level is
consistently and independently from traditional risk factors
related to cardiovascular risk [1]. Fibrinogen has emerged as
an important additional marker for stratification of cardio-
vascular event risk. The analysis compromising participant
data from 52 prospective studies showed that the assessment
of fibrinogen in people at intermediate risk for cardiovas-
cular event could help prevent one additional event over a
period of 10 years for every 400–500 people so screened [2].
In stroke patients higher levels of plasma fibrinogen are
associated with increased risk of unfavourable functional
outcome [3–8], short-term mortality [3–5, 9] and new
cardiovascular events [10–12].
Much less is known about the association between
hyperfibrinogenemia and long-term mortality after stroke. In
one study, the ischemic stroke patients with hyperfibrinoge-
nemia were more likely to die after 12 months than those with
normal plasma fibriniogen and the increased fibrinogen con-
centration was an independent predictor of death [3]. From
clinical point of view it is important to determine if increased
plasma fibrinogen level is related to long-term mortality after
stroke. First, fibrinogen could serve as a biomarker to identify
patients who are at risk of death. Such patients may require
careful monitoring and more aggressive secondary preven-
tion. Second, fibrinogen can be considered as potential ther-
apeutic target, because its level could be reduced by smoking
cessation, diet, physical activity and some drugs.
The aim of our study was to determine the relationship
between plasma fibrinogen level and long-term risk of
death in ischemic stroke patients.
Materials and methods
We retrospectively analysed the prospectively collected
data on prognosis in stroke patients. The consecutive
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patients with first-ever ischemic stroke admitted to our
stroke unit within 24 h after stroke onset were eligible for
the study. The patients were recruited to the study between
November 2004 and October 2007. The only exclusion
criterion was the lack of patient’s consent for participation
in the study.
All patients underwent head CT scan within 24 h
after stroke onset. Stroke severity on admission was
assessed using National Institute of Health Stroke Scale
(NIHSS).
Arterial hypertension was diagnosed when its presence
was documented in medical records or when at least two
readings of blood pressure were C140 mmHg (systolic) or
C90 mmHg (diastolic) after the acute phase of stroke. The
diagnosis of diabetes mellitus was made when (1) the
patient had the recognized diabetes mellitus before stroke
as written in medical records and/or took hypoglycemic
drugs before stroke; (2) fasting plasma glucose measured
on day 6–10 was C7.0 mmol/L or fasting plasma glucose
was 6.1–6.9 mmol/L and 2 h plasma glucose was
C11.1 mmol/L after oral glucose tolerance test. A patient
was defined as a smoker if there was a history of cigarette
smoking during the last 5 years.
Plasma fibrinogen level was determined on day 1 using
modified Clauss method (Dade Behring, Marburg, Ger-
many). Hyperfibrinogenemia was defined as plasma con-
centration [3.5 g/L.
The follow-up was up to 84 months with the minimal
duration of 12 months. Information about death was taken
from the town registry.
The study protocol was approved by the local Bioethics
Committee and each participant gave the informed consent.
The v2 test was used to compare proportions and Mann–
Whitney’s test to compare continuous variables between
groups. Values of less than 0.05 were considerate to indi-
cate statistical significance. Log-rank test was used to
compare survival between the patients with hyperfibrino-
genemia and those with normofibrinogenemia. Cox’s pro-
portional hazard models were used to find the independent
predictors of death on univariate and multivariate analysis.
The variables with P \ 0.10 on univariate analysis were
included in multivariate analysis. The calculations were
performed using the program STATISTICA for Windows
(version 10, Statsoft, Poland).
Results
Seven hundred thirty six patients fulfilled the inclusion
criteria (median age 71, interquartiles 62–79; 47.1 % men).
Hyperfibrinogenemia was found in 184 (25.0 %) patients.
Table 1 shows the characteristic of patients with hyperfi-
brinogenemia and those without it.
The patients with hyperfibrinogenemia more often were
male, suffered from previous myocardial infarction, had
white blood cell count [10,000/lL and the body temper-
ature [37.5 C during first 48 h of stroke.
Figure 1 shows Kaplan–Meier’s curves of survival for
the patients with hyperfibrinogenemia and the patients with
normofibrinogenemia. The patients with hyperfibrinoge-
nemia had shorter time of survival than those with nor-
mofibrinogenemia (P \ 0.01, log-rank test).
Table 2 shows independent predictors of death on uni-
variate analysis.
Hyperfibrinogenemia was associated with risk of death
both on univariate (HR 1.62, 95 % CI 1.28–2.07, P \ 0.01)
and multivariate analysis (HR 1.71, 95 % CI 1.29–2.26,
P \ 0.01). Other independent predictors of death on mul-
tivariate analysis were: age (HR 1.03, 95 % CI 1.01–1.04,
P \ 0.01), NIHSS score (HR 1.08, 95 % CI 1.05–1.10,
P \ 0.01), atrial fibrillation (HR 1.62, 95 % CI 1.20–2.18,
P \ 0.01), white blood cell count count [10,000/lL (HR
1.32, 95 % CI 1.02–1.71, P = 0.03) and the body tem-
perature [37.5 C during first 48 h of stroke (HR 1.48,
95 % CI 1.13–1.92, P \ 0.01).
Discussion
In our study hyperfibrinogenemia was associated with
long-term risk of death after ischemic stroke and this
relationship was independent from age, stroke severity, and
selected inflammation-related variables (fever, leukocyto-
sis, in-hospital pneumonia). New information provided by
our study is that in relatively large cohort of unselected
ischemic stroke patients hyperfibrynogenemia predicts
mortality beyond 1 year.
The results of a few studies indicate that hyperfibrino-
genemia observed in acute stroke persists even 1 year after
the event. It suggests that the stimuli for fibrinogen syn-
thesis are still active even months after cerebral infarction
[13, 14]. Levels of fibrinogen are influenced by genotype
and therefore persistent hyperfibrinogenemia could be
related to variation in genomic sequences [15, 16]. Finally,
the elevated levels of fibrinogen observed months after
stroke might reflect pre-stroke hyperfibrinogenemia which
is considered as a risk factor for stroke [17, 18].
Our findings should be interpreted in light of the results
of the studies investigating the relationship between
fibrinogen and mortality in non-stroke populations. In large
individual participant meta-analysis, moderately strong
association was found between plasma fibrinogen and the
risk of vascular and non-vascular mortality in healthy
middle age adults [18]. In EPIC-Norfolk study including
16,850 participants aged 40–79, fibrinogen level predicts
long-term risk of death after adjustment of cardiovascular
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risk factors [19]. Higher fibrinogen concentration was also
associated with increased risk of death in patients with
unstable angina [20], diabetes mellitus [21] or renal failure
[22, 23]. Taking together, these results suggest that plasma
fibrinogen level is a non-specific marker of mortality and
bring the causal link between hyperfibrinogenemia and
increased risk of death in question.
Table 1 The baseline
characteristics of the patients
with and those without
hyperfibrinogenemia
Patients with
normofibrinogenemia
(N = 552)
Patients with
hyperfibrinogenemia
(N = 184)
P
Age, median (IQ) 70.0 (63.0–78.0) 71.5 (62.0–81.0) 0.32
Men, n (%) 243 (44.0) 104 (56.5) \0.01
Hypertension, n (%) 375 (67.9) 124 (67.4) 0.89
Diabetes mellitus, n (%) 115 (20.8) 37 (20.1) 0.83
Previous myocardial infarction, n
(%)
64 (11.6) 33 (17.9) 0.03
Atrial fibrillation, n (%) 127 (23.0) 30 (16.3) 0.05
Smoking, n (%) 145 (26.3) 55 (29.9) 0.34
NIHSS score on admission, median
(IQ)
11.0 (6.8–17.0) 12.0 (8.0–17.0) 0.18
Systolic blood pressure on admission
(mmHg), median (IQ)
160 (140–180) 160 (140–180) 0.83
Diastolic blood pressure on
admission (mmHg), median (IQ)
90 (80–100) 90 (80–100) 0.26
Glucose on admission [7.0 mmol/L,
n (%)
224 (40.5) 78 (42.4) 0.65
Fasting glucose [6.1 mmol/L, n (%) 225 (40.8) 82 (44.6) 0.42
Total cholesterol (mmol/L), median
(IQ)
5.3 (4.5–6.2) 5.3 (4.5–6.4) 0.93
Body temperature [37.5 C during
first 48 h, n (%)
122 (22.1) 57 (30.9) 0.02
WBC count [10 000/lL, n (%) 150 (27.2) 77 (41.8) \0.01
In-hospital pneumonia, n (%) 58 (10.5) 17 (9.2) 0.62
Fig. 1 Kaplan–Maier survival curves for the patients with and those
without hyperfibrinogenemia
Table 2 The predictors of death on univariate analysis
HR, 95 %CI P value
Age (increase per unit) 1.03 (1.02–1.04) \0.01
NIHSS score on admission (increase per
unit)
1.09 (1.07–1.11) \0.01
Atrial fibrillation 1.75 (1.37–2.25) \0.01
Smoking 0.69 (0.54–0.89) \0.01
WBC count [10 000/lL 1.46 (1.17–1.83) \0.01
Body temperature [37.5 C during first
48 h
2.03 (1.60–2.58) \0.01
In-hospital pneumonia 2.53 (1.90–3.37) \0.01
Hyperfibrinogenemia 1.62 (1.28–2.07) \0.01
Fasting glucose [6.1 mmol/L 1.73 (1.38–2.18) \0.01
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It remains unclear if hyperfibrinogenemia in stroke
patients is only a marker of mortality or a real culprit. The
assessment of any causal relationship of fibrinogen level
with mortality in stroke patients will require randomized
trials of selective fibrinogen-lowering drugs or Mendelian
randomization studies assessing genetic determinants of
fibrinogen level.
Fibrinogen levels can be reduced by lifestyle modifica-
tion (for example, smoking cessation, regular exercises,
diet, etc.) or medication (for example, fibrates). Taking into
account the persistence of hyperfibrinogenemia after stroke
and its relationship to death, any interventions aimed to
decrease post-stroke mortality by lowering fibrinogen lev-
els should be long-lasting.
In conclusion, hyperfibrinogenemia predicts the long-
term risk of death in ischemic stroke patients.
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